Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ACCELERATE DIAGNOSTICS, INC.

(AXDX)
  Report
Real-time Estimate Cboe BZX  -  10:39 2022-09-27 am EDT
1.670 USD   +3.73%
09/19Accelerate Diagnostics, Inc.(NasdaqCM:AXDX) dropped from S&P Global BMI Index
CI
08/23Accelerate Diagnostics, Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/19Accelerate Diagnostics Prices Underwritten Offering of Common Stock at $2/Share; Shares Sink Friday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Accelerate Diagnostics scheduled call to review 2022 second quarter results

07/25/2022 | 09:31am EDT

TUCSON, Ariz., July 25, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, August 15, 2022, at 4:30 p.m. Eastern Time to review 2022 second quarter results.

To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available until November 15, 2022.

To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 8181593. International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference.

A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the replay code 5773022 until September 6, 2022.

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antimicrobial resistance and sepsis. The Accelerate Pheno® system and Accelerate Arc™ system are designed to reduce the time clinicians must wait to determine the most optimal antibiotic therapy for bacteremic patients. These diagnostic systems are designed to serve clinical laboratories with automated solutions to expedite time to identification and antimicrobial susceptibility test (AST) results directly from positive blood culture samples. Multiple external studies have proven that Accelerate solutions deliver results 1 to 2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient's infection, days earlier.

The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and "ACCELERATE PHENOTEST" and "ACCELERATE ARC" and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.

For more information about the company, its products and technology, or recent publications, visit axdx.com.

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2022-second-quarter-results-301590275.html

SOURCE Accelerate Diagnostics, Inc.


© PRNewswire 2022
All news about ACCELERATE DIAGNOSTICS, INC.
09/19Accelerate Diagnostics, Inc.(NasdaqCM:AXDX) dropped..
CI
08/23Accelerate Diagnostics, Inc : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
08/19Accelerate Diagnostics Prices Underwritten Offering of Common Stock at $2/Share; Shares..
MT
08/18Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock
PR
08/18Sector Update: Health Care Stocks Unable to Reach Positive Ground
MT
08/18Sector Update: Health Care
MT
08/18Top Midday Decliners
MT
08/18Accelerate Diagnostics Slumps After Initiating Stock Offering
MT
08/18Top Premarket Decliners
MT
08/18Accelerate Diagnostics Initiates Stock Offering
MT
More news
Analyst Recommendations on ACCELERATE DIAGNOSTICS, INC.
More recommendations